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Abstract The objective of this work was to facilitate the
development of nonlinear mixed effects models by estab-
lishing a diagnostic method for evaluation of stochastic
model components. The random effects investigated were
between subject, between occasion and residual variability.
The method was based on a first-order conditional esti-
mates linear approximation and evaluated on three real
datasets with previously developed population pharmaco-
kinetic models. The results were assessed based on the
agreement in difference in objective function value
between a basic model and extended models for the stan-
dard nonlinear and linearized approach respectively. The
linearization was found to accurately identify significant
extensions of the model’s stochastic components with
notably decreased runtimes as compared to the standard
nonlinear analysis. The observed gain in runtimes varied
between four to more than 50-fold and the largest gains
were seen for models with originally long runtimes. This
method may be especially useful as a screening tool to
detect correlations between random effects since it sub-
stantially quickens the estimation of large variance–
covariance blocks. To expedite the application of this
diagnostic tool, the linearization procedure has been auto-
mated and implemented in the software package PsN.
Keywords Linearization  Random effects  Nonlinear
mixed effects models  Pharmacometrics  Diagnostics
Introduction
Population pharmacokinetics (PK) and pharmacodynamics
(PD) models, i.e. pharmacometrics, play an increasingly
important role in pharmaceutical sciences and drug
development [1]. Nonlinear mixed effects (NLME) models
are frequently used to describe population PK/PD and are
composed of a structural component (fixed effects) and a
stochastic component (random effects). Fixed effects
describe the typical parameter values in a population and
the effects of covariates. Random effects handle unex-
plained variability and can be further divided into vari-
ability assigned to parameters and residual variability (RV)
assigned to the observations. Parameters can vary on
multiple levels: between subjects (BSV), between occa-
sions (BOV), between studies, etc.
For NLME, especially when used in simulations, the sto-
chastic components of the model are crucial but the devel-
opment procedure can be laborious. Despite a vast increase in
available computational power during the past decade, the
time for parameter estimation can still be a limiting factor
since the complexity of the used models and the amount of
fitted data typically are increasing likewise. For highly non-
linear models numerical instability of parameter estimation
with common gradient based, local methods may cause fur-
ther problems. Individual parameter estimates, the empirical
Bayes estimates (EBEs), can be used as a diagnostic tool to aid
the development procedure. However, this practice has nota-
ble shortcomings when data are uninformative on the indi-
vidual level and shrinkage towards the population mean
occurs. Shrinkage can cause diagnostics based on EBEs to
mask, falsely induce or distort the shape of random effects
relationships [2, 3]. The objective of this work was to develop
and assess a fast and stable method which is not sensitive to
shrinkage for diagnostics of BSV, BOV and RV model
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components. The here proposed method, henceforth called
‘linearization’, is based on a first-order conditional estimation
(FOCE) linear approximation which has previously success-
fully been applied for testing of covariates [4]. The lineari-
zation was evaluated in the modeling software NONMEM
with a variety of different models and datasets. The results are
presented as comparisons between the linearization and the
corresponding nonlinear model, both in terms of estimation
performance and runtimes.
Methods
Population models and linearization
NLME models commonly used in population PK/PD can
be formally represented by
yij ¼ f ð p!i; x!ijÞ þ hij ð1Þ
where yij is the data point of the ith individual’s jth
observation, f is a model that relates the vector of indi-
vidual parameters p~i and the vector of independent vari-
ables x~ij (for example dose and time) to the observations
and hijis a model for the residual error. The individual
parameters can be described as
p!i ¼ p! h
!





where p~ is the vector of models relating the typical
parameter values in the population h~, the parameter-spe-
cific variability g~i and the vector of covariate functions g~,
including covariate observations z~i and typical population
values for respectively covariate-parameter relation h~g~. The
parameter-specific variability can have multiple levels
simultaneously and is usually assumed to be normally
distributed with mean 0 and variance–covariance matrix X.
BSV and BOV are frequently modeled by assuming an
exponential relationship to obtain log-normal parameter
distributions. Under this assumption, parameter k in indi-
vidual i with L levels of parameter-specific variability can
be describe by the following model








The residual error model is commonly modeled as a
function of e~ij which is assumed to be normally distributed
with mean 0 and variance–covariance matrix R. Common
forms of hij are additive error (hij = eij), proportional error
ðhij ¼ f p~i; x~ij
  eijÞ or a combined error with both an
additive and a proportional element ðhij ¼ f p~i; x~ij
 
e1ij þ e2ijÞ. Examples of extensions and more flexible forms
have been described in the following references [5–8].
Model parameters can be obtained by maximum likeli-
hood estimation where the estimated parameter values
maximizes the likelihood of the observed data [9]. Maxi-
mizing the likelihood is equivalent to minimizing the twice
negative log-likelihood (objective function value, OFV).
Evaluation of the function for the log-likelihood of NLME
models require integration steps that are computationally
demanding and a simpler linear approximation of the
model can be evaluated instead. We here assess the pos-
sibility of utilizing partial derivatives and EBEs from
evaluation of a nonlinear base model to assess the
improvement in model fit by additional random effects
through estimation of extensions implemented on the linear
approximation of the base model. The linear approximation
consists of first-order Taylor expansions initially around
e~ij ¼ 0~ (Eq. 4) and subsequently around g~i ¼ g^~ where g^~i
represents the EBE’s of g~i (Eq. 5, the linearized model).













































where Q0 ¼ ðe~ij ¼ 0~; g~i ¼ g^~iÞ, m is the number of element
in g~i and s is the number of elements in e~ij: The partial
derivatives and EBE’s are obtained by evaluating the
nonlinear base model with the first order conditional esti-
mation method with interaction (FOCE-I) in NONMEM
(see section Software). If the error model is simply additive
FOCE without interaction can be used. The FOCE and
FOCE-I methods also utilize Taylor expansions and are
described in NONMEM users guide-part VII [10]. The
parameters marked with asterisks in Eqs. 4 and 5 are the
unknown parameters of the linearized model that remain to
be estimated. A comprehensive example code is provided
as supplementary material. Since the iterative calculation
of fixed effects parameters and partial derivatives are time
consuming steps, especially for models including large
variance–covariance matrixes, the estimation of a before-
hand linearized extended model (where iterative calcula-
tions only are needed for the random effects) is magnitudes
faster than estimation of the nonlinear extended model.
Software
NONMEM versions 7.2 and 7.3 beta (ICON Development
Solutions, Hanover, MD, USA) [10] with the estimation
method FOCE-I were used for the analysis. To overcome
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sensitivity to local minima when estimating individual
parameters (g-values) the new NONMEM option MCETA
was utilized. The default initial value for all g is zero.
MCETA allows the user to define a number of vectors
containing random samples of initial g-values that should
be tested in addition to zero, whichever supplies the lowest
OFV will be used as initial value in the estimation. The
numbers in each vector of initial g-values are randomly
drawn from the normal distribution with mean zero and
variance–covariance matrix X. With a large enough num-
ber of initial g-values tested, the probability of the esti-
mation to end up in a local minimum can be decreased.
Models were executed through PsN, using Piranha for
documentation and creation of run records [11–13].
Evaluated model extensions
A comprehensive overview of the work flow for comparing
standard nonlinear and linearized models is given in Fig. 1.
The evaluated RV models were extensions to an additive, a
proportional or a combined base error model. The evalu-
ated extensions were:
• BSV of the residual error [14]
• A power relation with the individual model predictions
(F), implemented as hij ¼ hijðbaseÞ  Fh
• Autocorrelation, i.e. serial correlation between the error
of observations consecutive in time [5]
• Time dependent residual error, implemented as a step
function [5]
The NONMEM code of the RV extensions is provided
in the supplementary material. For extensions of the BOV
and/or the correlation structure, a base model already
including some BSV terms was used while for extensions
of the BSV structure the base model only included RV. To
this model additional parameter-specific variability were
added and/or the structure of the variance–covariance
block changed. To enable estimation of the linearized
model with additional variability parameters, the partial
derivatives of the model with respect to the new parameters
must be known. The partial derivatives can be obtained in
NONMEM by including the code for the additional vari-
ability parameters already in the nonlinear base model but
fixed to an arbitrary small value (fixing it to zero would
result in that no derivatives are calculated).
All extended models were estimated with FOCE-I both
in the linearized form and as standard nonlinear models.
The results were evaluated by comparing the difference in
OFV (DOFV) between the extended model and the base
model for the two approaches respectively. The runtimes
for the estimation step were extracted from the result files.
The runtime comparisons should be interpreted in terms of
magnitude and not as exact figures, since all estimations
were carried out at a cluster with many nodes, which have
somewhat different capacities and are randomly assigned.
Fig. 1 Work flow to compare performance of nonlinear and linearized models in NONMEM
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Datasets
Three real data examples with previously developed
models with diverse residual error structures were used to
illustrate the methodology.
1. Moxonidine [14]: The data were obtained from a phase
II multicenter study of oral moxonidine in patients
with congestive heart failure and contained 1,022
observations from 74 patients. The structural model
describing the data was a one-compartment model with
first-order absorption and an additive residual error
model.
2. Pefloxacin [15, 16]: The data were obtained from
critically ill patients receiving 1 h intravenous infu-
sions of pefloxacin and contained 337 observations
from 74 patients. The structural model was a one-
compartment model and a proportional residual error
model.
3. Ethambutol [17]: The data were obtained from two
prospective studies in tuberculosis patients receiving a
standard treatment regimen including ethambutol. A
total of 1869 observations from 189 patients were
included in the dataset. The structural model was a
one-compartment model with first-order absorption
through one transit compartment and a combined
residual error model.
Results
The agreement between the DOFV of the nonlinear and the
linearized extended RV models were found to be good
(Fig. 2a). Also for extended correlations structures the
agreement was good (Fig. 2d). For extended BSV and
BOV models the agreement was acceptable (Fig. 2b, c).
The deviations between the nonlinear and linearized model
were the largest for instances where the value of one or
several fixed effect parameter(s) in the nonlinear model
were notably changed by the extension. The extended
linearized models do not allow a change of the fixed effects
since those values are incorporated in the predictions and
derivatives obtained from the base model. The linearized
analysis identified the same extended models to be signif-




Fig. 2 Difference in OFV between base and various extended RV (a), IIV (b), IOV (c) and covariance (d) models (described in methods), after
estimation with the nonlinear vs. the linearized approach for the moxonidine (black triangles), pefloxacin (grey squares) and ethambutol (open
circles) data examples
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in all cases except in four, resulting in an accuracy of 96 %
(88 of 92). In the four deviating cases the DOFVs were
very close to the significance level (following Chi square
distribution, a = 0.05).
The total runtimes for the linearized models using the
three example datasets were markedly shorter compared to
the corresponding nonlinear models (Table 1). When the
linearization of the base model is successful, the OFV
value of the linearized version and that of the corre-
sponding nonlinear model estimated with FOCE-I should
be very similar. This was the case for all evaluated models
with an additive residual error model. However, for models
with proportional or combined residual error models, a
number of cases were discovered where the OFV values
differed greatly and a lower OFV value was obtained for
the nonlinear base model. Closer evaluation of the results
revealed that this deviation between OFV values was
caused by certain subjects for whom the individual con-
tributions to the OFV (iOFV) were notably higher, whereas
for the majority of subjects the iOFV values of the two
methods matched well. For the deviating subjects the
estimation of individual g-values had failed in the linear-
ized model due to issues with local minima. Transforma-
tion to render the error additive in the transformed space or
utilization of the MCETA option resolved the problem for
all evaluated cases.
Discussion
A novel diagnostic method for evaluation of random
effects was successfully developed and evaluated. The
linearization was found to accurately identify significant
extensions of models’ stochastic components with notably
decreased runtimes as compared to standard nonlinear
analysis. The three examples used had relatively short
runtimes also in their nonlinear form. When the lineariza-
tion was applied to more complex models, an even more
substantial decrease in runtimes ([509) was observed. For
a PD-model describing the effect of docetaxel on neutro-
phil counts (extension of [18] ) utilizing the full random
effects approach (FREM [19] ) the runtime was decreased
from 3 h and 50 to 5 min (2.2 %). For a PK model of
bedaquiline plus two metabolites including a large
covariance block (extension of [20] ) the runtime was
reduced from 15 h and 52 to 6 min (0.6 %). For a PK-
model of rifabutin plus metabolite using a dataset com-
bining 14 clinical studies (unpublished) for which the
runtime of the base nonlinear model was several day, the
estimation of 6 additional BSV parameters and extending
the variance–covariance matrix from a diagonal to a full
12 9 12 block structure took only 18 and 89 min,
respectively.
When applied to models with a proportional or a com-
bined residual error structure the linearization was found to
be sensitive to local minima when assigning the individual
g-values. This happens due to the potential shape distortion
of the individual EBE likelihood profiles that can be caused
by the interaction term (including the partial derivative
with respect to both e and g of the residual error model) in
the linearized model. The interaction term will always be
zero for additive residual error models which explains why
the problem was never observed in this case. Care must be
taken to ensure that the OFV of the linearized base model
agrees with the corresponding nonlinear model. If a devi-
ation is detected, simple work-arounds can preclude
potential deviations. Transformations can render the error
model additive in the transformed space, for example log-
transformation for model with proportional error structure.
Another solution is the MCETA option, available in
NONMEM from version 7.3.0 [21], which decreases the
risk of issues with local minima by supplying multiple
initial estimates for the individual g-values. With MCETA
values of between 10 and 1,000 all evaluated linearized
models were able to obtain the same OFV value as the
corresponding nonlinear model. However, run times were
somewhat increase by use of the MCETA option. Yet
another potential solution could be to input the EBE’s from
the nonlinear base model as initial estimates for individual
g-values in the linearized model. This is possible with the
ETAS option, also available in NONMEM from version
7.3.0. The ETAS option should be faster than the MCETA
option since it only tests one set of initial estimates instead
of several, but it may be less reliable. In cases when the
shape of the likelihood profiles contain multiple local
minima, as have been observed for linearized models with
proportional or combined error structures, the risk of ter-
minating in local minima is substantial even with initial
estimates close to the optimal values and therefore the use
of the MCETA option could be safer.
To simplify the use of this novel methodology, an option
called ‘linearize’ has been implemented in PsN (available
from version 3.7.0). The procedure requires the provision
of a nonlinear model, optimizes the parameters and outputs
predictions and derivatives in a new dataset. This dataset
Table 1 Comparison of total runtimes for nonlinear and linearized








Moxonidine 735.1 106.5 14.5
Pefloxacin 47.78 6.96 14.6
Ethambutol 103082 25983a 25.2
a Executed with MCETA = 1,000
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constitutes the input for an automatically created linearized
version of the same model. The linearized model can serve
as starting point for evaluation of manually coded exten-
sions of the random effects. Model building could poten-
tially be made even more efficient by automated testing of
a library of RV models, comparable to the stepwise
covariate search method (the SCM) already implemented
in PsN. Since the values of fixed effects are not estimated
in the linearized model the method should be viewed as a
diagnostic tool. It is recommended to re-estimate with
standard nonlinear methods once the best extended model
is identified.
In conclusion, the successful use of a linear approxi-
mation method for fast diagnosis of a broad range of
extended random effects models was demonstrated. The
method may be especially valuable as a screening tool to
detect correlations between random effects since estimat-
ing large variance–covariance blocks often is a computa-
tionally demanding and time-consuming process but can be
carried out magnitudes faster with the linearization.
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